Sagimet Biosciences

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical firm zeroing in on diseases that stem from dysfunctional metabolic pathways. Founded in 2006 as 3-V Biosciences, Inc. and rebranded in August 2019, the company is strategically focused on developing a portfolio of selective fatty acid synthase (FASN) inhibitors. The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006. A significant milestone was achieved in July 2023 when the company executed an upsized initial public offering, raising gross proceeds of $85.0 million by listing on the Nasdaq Global Market under the ticker symbol “SGMT”.

The company's business model is centered on the research and development of proprietary drug candidates, with revenue generated through strategic licensing agreements and milestone payments. A key example is a strategic licensing deal with Ascletis Bioscience for the development rights of its lead drug in Greater China. As a clinical-stage entity, its financial performance is characterized by significant investment in research and development, leading to operating losses while it works to bring its products to market. The company's primary clients are patients suffering from metabolic diseases with high unmet needs, particularly those with metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).

Sagimet's lead product candidate is denifanstat, an oral, once-daily pill. This drug is a selective FASN inhibitor designed to address the overproduction of palmitate, a fatty acid implicated in various diseases. The mechanism of action for denifanstat is to reduce the three primary drivers of MASH: fat accumulation, inflammation, and fibrosis. Clinical trial results have been promising; the Phase 2b FASCINATE-2 trial demonstrated that denifanstat achieved statistically significant improvements in MASH resolution without worsening of fibrosis. In addition to MASH, for which there are currently no approved treatments in the U.S. or Europe, Sagimet is exploring the potential of its FASN inhibitors for other indications, including various solid tumor cancers and acne.

Keywords: Sagimet Biosciences, clinical-stage biopharmaceutical, FASN inhibitors, denifanstat, metabolic dysfunction-associated steatohepatitis, MASH, NASH, fatty acid synthase, liver fibrosis, metabolic pathways, palmitate, oncology, acne treatment, clinical trials, biopharmaceutical R&D, metabolic disease therapeutics, SGMT, oral drug development, liver disease treatment, lipid metabolism, denifanstat clinical data